Mark Barlow
Trustee, MND Association, UK
I was diagnosed with MND in July 2023 and my background is in the healthcare industry, having spent 23 years in pharmaceuticals with Sanofi and its predecessor companies and 15 years in the MedTech industry working for GE Healthcare.
Most of my career has been spent working in the neurology domain, launching drugs and diagnostics for conditions such as epilepsy, multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease and Stroke. When I worked at Aventis, a predecessor of Sanofi, my team was responsible for successfully getting riluzole through its NICE appraisal in 2001. I was also a Board member of the European Brain Council for a number of years.